BACKGROUND: Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. METHODS: In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. RESULTS: A total of 213 patients (95.1%) completed the study. From weeks 12 - 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. CONCLUSION: The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. TRIAL REGISTRATION: This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668.

Biogen Cambridge MA USA

Faculty of Pharmaceutical Medicine London UK

Kansai Medical University Medical Center Osaka Japan

Kansai Multiple Sclerosis Centre Kyoto Min iren Central Hospital Nishinokyo Kasuga cho 16 44 409 Nakakyo ku Kyoto 604 8453 Japan

NCNP National Center Hospital Tokyo Japan

Sanofi Cambridge MA USA

Zobrazit více v PubMed

Gold R, Kappos L, Arnold DL. Bar-or A, Giovannoni G, Selmaj K, et al; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107. PubMed

Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. CONFIRM study investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097. doi: 10.1056/NEJMoa1206328. PubMed DOI

Tibung JT, Nestorov I, McNeill M, Li J, Zhu B. An open-label, parallel-group, phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of dimethyl fumarate in Chinese, Japanese, and Caucasian adult healthy volunteers. Mult Scler. 2016;22:422.

Nakashima I, Fukazawa T, Ota K, Nohara C, Warabi Y, Ohashi T, et al. Two subtypes of optic-spinal form of multiple sclerosis in Japan: clinical and laboratory features. J Neurol. 2007;254:488–492. doi: 10.1007/s00415-006-0400-z. PubMed DOI

Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci. 1981;49:253–271. doi: 10.1016/0022-510X(81)90083-6. PubMed DOI

Houzen H, Niino M, Hirotani M, Fukazawa T, Kikuchi S, Tanaka K, et al. Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan. J Neurol Sci. 2012;323:117–122. doi: 10.1016/j.jns.2012.08.032. PubMed DOI

Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol. 2016;29:222–228. doi: 10.1097/WCO.0000000000000328. PubMed DOI

Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al. Research Committee of Neuroimmunological Diseases. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler. 2009;15:159–173. doi: 10.1177/1352458508098372. PubMed DOI

Kim SH, Kim HJ. Central nervous system neuroinflammatory disorders in Asian/Pacific regions. Curr Opin Neurol. 2016;29:372–380. doi: 10.1097/WCO.0000000000000315. PubMed DOI

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International panel for NMO diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–189. doi: 10.1212/WNL.0000000000001729. PubMed DOI PMC

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703. PubMed DOI

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444. PubMed DOI

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–1489. doi: 10.1212/01.wnl.0000216139.44259.74. PubMed DOI

Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. BG-12 phase IIb study investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372:1463–1472. doi: 10.1016/S0140-6736(08)61619-0. PubMed DOI

Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. Lancet Neurol. 2013;12:669–676. doi: 10.1016/S1474-4422(13)70103-0. PubMed DOI

Sormani MP, Tintore M, Rovaris M, Rovira A, Vidal X, Bruzzi P, et al. Will Rogers phenomenon in multiple sclerosis. Ann Neurol. 2008;64:428–433. doi: 10.1002/ana.21464. PubMed DOI

Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an international CMSC consensus conference, March 5-7, 2010. Int J MS Care. 2012;14:105–14. PubMed PMC

Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, et al. DEFINE and CONFIRM study investigators. Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis. Eur J Neurol. 2015;22:664–671. doi: 10.1111/ene.12624. PubMed DOI PMC

Fox RJ, Chan A, Gold R, Phillips JT, Selmaj K, Chang I, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6:220–229. doi: 10.1212/CPJ.0000000000000238. PubMed DOI PMC

Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, et al. Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate. Int J MS Care. 2015;17:236–243. doi: 10.7224/1537-2073.2014-069. PubMed DOI PMC

Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01838668